Misonix (NSDQ:MSON) shares are up 19% today after the medical device company swung to black ink for its fiscal 4th quarter and full year.
Farmingdale, N.Y.-based Misonix posted profits of $366,000, or 5¢ per share, on sales of $1.7 million for the 12 months ended June 30 – for a 26.7% top-line gain that helped Misonix swing from a $3.5 million loss during its last fiscal year.
For its fiscal 4th quarter, Misonix reported profits of $445,000, or 6¢ per share, on sales of $5.3 million, another swing to black ink and a 40.8% sales increase, compared with the same period last year.
Sign up to get our free newsletters delivered straight to your inbox
"Our strategic goal has been to transition Misonix to be a focused surgical device company – and we have succeeded in achieving that goal. Going forward we have 3 main goals: Continue to successfully place instruments throughout the surgical community worldwide; substantially grow recurring revenues through the sale of disposables; and continue to expand our worldwide distribution system," president & CEO Michael McManus Jr. said in prepared remarks. "For fiscal the year U.S. sales increased 12% while international sales increased 58% as our expanding distribution channel throughout the world becomes more fully engaged in the sales process."
MSON shares closed up 19.1% at $3.68 on Wall Street today.
EMD Millipore buys stem cell tech
Merck’s (NYSE:MRK) EMD Millipore subsidiary paid an undisclosed amount for non-exclusive rights to iPS Academia Japan’s induced pluripotent stem cell patent portfolio, developed by Dr. Shinya Yamanaka of Kyoto University’s Center for iPS Cell Research and Application.
Read more
SteadyMed, SpinalMotion land $24M
San Francisco-based SteadyMed Therapeutics said it reeled in $10.4 million to develop its PatchPump drug delivery implant; SpinalMotion, which won CE Mark approval in the European Union for 2 of its Kineflex cervical disc implants in March, said it pulled down $13.6 million from 15 unnamed investors.
Read more
Biomet adds $825M to debt offering
Biomet said it plans to offer $825 million worth of 6.5% senior notes due 2020 as a follow-on to the $1.0 billion in 6.5% senior notes due 2020 issued on August 8.
Read more
BrainScope lands $3M Army contract
BrainScope Co. said won a 2-year U.S. Army contract worth $2.7 million to develop a "miniature field-deployable system for rapid TBI assessment."
Read more
Analysts’ ups and downs
- Abbott (NYSE:ABT): Leerink Swann downgrades from “outperform” to “market perform” rating, lowers price target from $70 to $65-$70.
- Boston Scientific (NYSE:BSX): Leerink Swann downgrades from “outperform” to “market perform” rating, maintains $6 price target.
- Smith & Nephew (FTSE:SN, NYSE:SNN): Sanford C. Bernstein reaffirms market perform rating, sets $11.13 (£6.90) price target.
